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Abstract. Migraine is a debilitating disorder affecting a large proportion of the population. The effect of methylenetrathydrofolate
reductase (GeneID: 4524) polymorphisms in migraine etiology and development has been a theme of great interest. Several
populations were evaluated with contradictory results. In this case-control study, we investigated the effect of the C677T
polymorphism in MTHFR, as a genetic risk factor for migraine, in the Portuguese population. We observed that, overall, there
was no significant difference in the frequencies of MTHFR C677T genotypes or of the T-allele among the Portuguese migraineurs
when compared to controls. There was also no association of migraine with aura with MTHFR genotypes or with the T-allele, in
contrast with previous studies. Regarding the risk of the T-allele homozygote carriers, there was an equal probability to develop
migraine with aura over migraine without aura in our patients. Thus, we conclude that the C677T MTHFR polymorphism,
responsible for a reduction of the MTHFR activity in folate metabolism, is not a major genetic susceptibility factor for migraine
in the Portuguese population.
Keywords: Migraine with aura, association study, folate metabolism, homocysteine, cephalalgia
Abbreviations: MA, migraine with aura; MO, migraine without aura; Hcy, homocysteine; TGV, trigeminovascular system.
1. Introduction
Migraine is a common neurovascular disease af-
fecting all age groups but mainly adolescents and
young adults. Along with the characteristic episodic
headaches, patients often experience nausea, vomiting,
photophobia and/or phonophobia. According to the In-
ternational Headache Society (IHS), there are two ma-
jor classes of migraine: migraine with aura (MA) and
migraine without aura (MO) [1]. The aura symptoms
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precede the head pain, when present, in MA patients,
and they usually correspond to visual or sensory distur-
bances [2].
Several studies were performed in order to define
the neuroanatomical involvement in migraine, to clar-
ify its molecular mechanisms and to define the modu-
lating factors influencing this neurovascular disorder.
A large set of data supports the concept that migraine
is partially associated with cerebral blood circulation
disturbances [3].
Increased levels of homocysteine (Hcy), a precursor
of excitatory amino acids, have been associated, among
others, with vascular integrity [4]. The level of Hcy
also affects the trigeminovascular system (TGV) by
increasing its firing rate as in response to pain. Since
the TGV has been strongly implicated in migraine [5],
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the excitatory effect of Hcy may affect the threshold for
migraine manifestation [4].
In humans, the total level of Hcy is determined both
by environmental and genetic factors [6]. The en-
zyme methylenetetrahydrofolate reductase (MTHFR,
EC 1.5.1.20) is involved in folate metabolism, cataly-
zing the reduction of 5–10 methyltetrahydrofolate to
5-methyltetrahydrofolate, an essential substrate for the
methylation of Hcy to methionine. Frosst et al. [6]
reported an association between a sequence variation
in the MTHFR gene (C677T) and plasma Hcy levels.
The common C677T substitution in MTHFR results in
an aminoacid replacement (A222V) in the catalytic do-
main that leads to increased enzyme thermolability and
concomitant activity reduction [6]. When dietary fo-
late intake is insufficient, the polymorphism-associated
reduction in enzyme activity may result in mild hy-
perhomocysteinemia [6]. For this reason, the effect of
MTHFR polymorphisms on the risk of developing mi-
graine has been a subject of great interest and mi-
graineurs of several populations have been evaluated
for this matter [7–13]. In this study, we performed a
case-control study to estimate the contribution of the
MTHFR C677T polymorphism to the risk of develop-
ing migraine in the Portuguese population.
2. Material and methods
2.1. Subjects
One hundred and eighty-six Portuguese, unrelated
migraine patients, 82% of whom females, with a mean
age of 36.2 ± 11.6 years, were examined and inter-
viewed by an experienced neurologist (J. P.-M.) be-
tween 2000 and 2003. These patients were clinically
diagnosed, based on the 1988 IHS criteria [1], as hav-
ing MA (78 cases, 42%, mean age 34.9 ± 14.4 years),
or MO (108 cases, 58%, mean age 36.4 ± 12.3 years).
The patients experiencing both subtypes of migraine
(22 cases, 12%) were included in the MA group. Pa-
tients with hemiplegic migraine were excluded from
this study. In the patients group, 161 (87%) had clini-
cal history of familial migraine. Informed consent was
obtained from all patients and the ethics committee of
the Santo Anto´nio Hospital approved the study. To
establish a control population that would be represen-
tative of the whole country, 50 Guthrie samples per
each of the 20 Portuguese districts were anonymously,
randomly and blindly selected from the national pro-
gram of phenylketonuria, congenital hypothyroidism
and other metabolic disordres screening (Guthrie blood
spots) biobank (kindly provided by Dr Laura Vilarin-
ho, IGM). Since the migraine patient group was main-
ly from the North of Portugal, all the Guthrie samples
collected from six districts comprising this sub-region
(Viana do Castelo, Braga, Porto, Vila Real, Braganc¸a,
Aveiro) were genotyped. For the remaining 14 dis-
tricts, the number of Guthrie card controls genotyped
was based on the population frequency of the district
in the global Portuguese population. Taken this, a con-
trol group (“Guthrie card controls”) was establish and
encompasses 397 anonymous samples of similar ethnic
background to that of the patients. We also genotyped
96 additional controls (blood donors) in whom mi-
graine was excluded and were matched for sex and eth-
nic background to that of the patient sample. Though
a direct age matching was not possible, the samples of
the blood donor group have a higher mean age (40.7±
10.8) of that of the patient’s group (34.9± 12.7).
2.2. Genotyping
The genomic DNA of patients and blood controls was
extracted from peripheral blood using standard meth-
ods. The genomic DNA from Guthrie card controls was
extracted from the filter paper blots using Chelex in a
final concentration of 0.8%. Amplification of the frag-
ment comprising the MTHFR C677T polymorphism
was carried out by PCR [6] using SEQ-MTHFRE4 for-
ward (5’-ACTGTCATCCCTATTGGCAGGTT-3’) and
MTHFRE4B reverse (5’-AGGACGGTGCGGTGAGA
GTGG-3’) primers. In the restriction analysis, PCR
products were digested with HinfI and then resolved in
an 8% non-denaturingpolyacrylamide gel, stained with
ethidium bromide and scanned with TYPHOON 8600
(GE Healthcare). Genotype comparisons were made
using a 25 pb DNA marker. Genotyping of the MTHFR
C677T polymorphism was performed by a researcher
who was unaware of the patient’s phenotype.
2.3. Statistical analysis
The frequency of MTHFR alleles and genotypes
were calculated using the SPSS program (version
14). Hardy-Weinberg equilibrium was tested for mi-
graineurs and control groups. Group comparison was
made with chi-square test and the level of signifi-
cance was set at P < 0.05. The risk of migraine for
carriers of the different MTHFR genotypes was as-
sessed by calculating the odds ratios (OR) with 95%
confidence intervals (CI).
A. Ferro et al. / The C677T polymorphism in MTHFR is not associated with migraine in Portugal 109
3. Results
A group of 186 unrelated migraineurs was com-
pared with two control groups of Portuguese origin:
the Guthrie card controls comprising 397 individuals
and the blood donor controls (n = 96) including sam-
ples from non-migraineurs individuals. The allele and
genotype frequencies of MTHFR observed in migraine
patients and in controls are summarized in Table 1.
The genotype frequencies of patients and both con-
trol groups were in Hardy-Weinberg equilibrium (mi-
graineurs: χ2 = 2.06, 1df, P = 0.15; Guthrie card
controls: χ2 = 0.37, 1df, P = 0.54; blood donor con-
trols: χ2 = 0.08, 1df, P = 0.78). When compar-
ing the distribution of CC, CT and TT genotype fre-
quencies in the migraine group in general (migraineurs,
42%, 49% and 9%) with the ones from the Guthrie
card control group (44%, 44% and 13%) we concluded
that they were not significantly different (χ2 = 2.54,
2df; P = 0.28). When the comparison was made with
the genotype frequencies in the control population ex-
cluded for migraine (blood donor control group, 36%,
49% and 15%), again, no significant differences were
observed (χ2 = 2.69, 2df; P = 0.26) (Table 1). The
direct comparison of TT genotype frequencies in the
two control populations also showed no statistical dif-
ferences (χ2 = 1.62, 2df; P = 0.45). When we com-
pared the frequency of T677T homozygote carriers in
the migraine sub-groups, MA (6%), MO (10%) and in
controls (13%, Guthrie card controls or 15% in blood
donor controls), again, no significant differences were
observed (χ2 = 2.65, 2df; P = 0.26 and χ2 = 3.06,
2df; P = 0.22, respectively) (Table 1). Consistently,
no enrichment of the risk T-allele was observed in the
migraineurs compared to the controls (Table 1). Di-
rect comparisons of TT homozygosity or risk T-allele
frequencies in MA versus MO or controls showed no
significant differences, indicating that no higher risk
for developing MA is associated with the T-allele (Ta-
ble 1). In the MA sub-group we found that the T-allele
was less represented (29%) than in both control groups
(35% in Guthrie card controls or 39% in blood donor
group), although with no statistical significance (χ2 =
1.47, 1df; P = 0.22 or χ2 = 3.48, 1df; P = 0.062),
respectively.
4. Discussion
Several studies have been performed to evaluate
the contribution of the C677T polymorphism in the
MTHFR gene to the risk of developing migraine (sum-
mary in Table 2). Kowa et al. [8] reported an associa-
tion of the TT-genotype with migraine in Japanese MA
patients. Kara et al. [7], observed an association of the
T-allele in homozygosity with the migraine, overall, but
failed to detect this association in Turkish MA patients,
in particular. Oterino et al. [10] found no association
of the TT-genotype in Spanish migraineurs overall, but
a two-fold risk of MA was reported to be associated
with the T-allele among the patients. Lea et al. [9]
observed, in a case-control study of unrelated patients,
a significant association of the TT-genotype with MA
in the sporadic migraineurs, as well as in the general
unrelated migraine group. Scher et al. [14] found, in
a population-based study, a significant increase in the
frequency of the TT-genotype among Dutch MA suffer-
ers when compared to controls and two large indepen-
dent studies reported no involvement of TT-genotype
in MA etiology for German [12] and Finnish [13] pa-
tients. The same positive association was reported for
MA in familial migraineurs when compared to unrelat-
ed healthy controls [9]. Population stratification and in-
appropriate control selection being major confounders
in association studies, it is important to notice that in
both family based case-control studies reported to date,
using a study design that is less sensitive to these issues,
the T-allele did not co-segregate preferentially with mi-
graine [9,12]. Consistently, Bottini et al. [11] reported
no association between this polymorphism in MTHFR
and migraine, or its sub-groups, in an Italian prospec-
tive study. More recently, a meta-analysis combining
all studies assessing the association of MTHFR C677T
polymorphism with migraine further suggests that the
TT-genotype is a genetic risk factor for MA, but not to
migraine overall [15].
In this case-control study, performed in the Por-
tuguese population, we did not observe an increased
susceptibility of the heterozygous or homozygous
MTHFR C677T carriers to migraine.
Moreover, a stratified analysis of the patients sam-
ple into MA and MO sub-groups also did not show
an increased risk for experiencing migraine with aura
among the patients with this genotype. We actually
observed an inverse proportion of the risk T-allele be-
tween the MA sub-group and the controls, with sub-
representation of the T-allele in MA, although this was
not statistically significant; this same trend has been
observed by Todt et al. in the German migraineurs [12].
These results do not completely rule out the possi-
bility of an association between this genetic polymor-
phism and migraine in our population: alone, this poly-
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morphism does not seem to confer an increased risk to
migraine in the Portuguese population, but it may do
so, synergistically, with other genetic or environmental
risk factors, which have not been evaluated yet. Never-
theless, we believe that our data is sufficient to exclude
a major effect of this polymorphism in the causality
of migraine in this population and to conclude that it
cannot be used on its own as a predictive factor, either
to measure the risk of migraine or to predict the clinical
presentation of the disease in affected individuals.
The T-allele frequencies detected in our control sam-
ples (35% in Guthrie card group and 39% in the blood
donor group) are consistent with other studies in Cau-
casian populations [9], indicating that both these con-
trol panels are appropriate ones, that may also be use-
ful for further studies. The fact that other studies with
smaller and modest sample populations were able to
observe association, when present, between MTHFR
C677T and migraine, makes us believe that the size of
our migraine population is not the major factor con-
tributing (negatively) to the overall outcome of this
study. No statistical difference was observed between
the two control groups studied and, although smaller,
the blood donor group comprised individuals exclud-
ed for migraine. Additionally, we have no reason to
expect that the larger control group (Guthrie card con-
trols), although not matched for age and sex with the
patient population, nor excluded for migraine could be
significantly enriched in migraineurs, since it was ran-
domly selected, thus not biasing the lack of associa-
tion observed. Interestingly, our study and the Span-
ish study did not report an association of the TT geno-
type with migraine and MA, when comparing to con-
trols. The common overall outcome may be a reflec-
tion of the genetic proximity reported for the two pop-
ulations [16]. Further studies concerning other known
MTHFR polymorphisms, genetic prothrombotic fac-
tors, and/or biochemical profiles, need to be carried out
in the Portuguese migraine patients in order to better
understand the gene-gene and gene-environment inter-
actions and improve our knowledge of the pathogenesis
of migraine.
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